Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection

Abstract

AIM. To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load. MATERIALS AND METHODS. The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions. RESULTS. The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA

Keywords

• hiv infection
• atazanavir
• darunavir
• single use
• immunological and virological efficacy